https://iridex.com RSS feeds for Iridex 60 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=63#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=63 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=63&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=63 Mountain View, CA -  May 31, 2024 -  Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, will showcase its latest non-incisional glaucoma treatments at the 16th European Glaucoma Society (EGS) Congress in Dublin, Ireland, from June 1-4, 2024. Attendees are invited to explore Iridex's glaucoma laser solutions at Booth #55. "We are pleased to take part in the EGS, where we will highlight our versatile laser platforms and advanced technologies, providing a continuum of care from early to end-stage glaucoma," said Steven J Koufos; Vice President, Global Marketing. MicroPulse Transscleral Laser Therapy (TLT) A versatile, non-incisional, and repeatable procedure for glaucoma treatment using the Iridex Cyclo G6® Laser System and MicroPulse P3® Delivery Device. Iridex-hosted MicroPulse TLT Drylab Session Sunday, June 2, 2024, titled “Non-incisional Glaucoma Treatment – The Versatility of MicroPulse Transscleral Laser Therapy” in Liffey Room 2, 10:30am-12:00pm Attendees of the Iridex-hosted MicroPulse TLT Drylab session will be able to explore the versatility of MicroPulse Transscleral Laser Therapy. For those unable to attend in person, we are also offering live streaming of the session via IPTV, providing global access to cutting-edge glaucoma treatments and innovations. Posters on Iridex-patented MicroPulse® Technology Comparison of one-year outcomes between combined micropulse transscleral diode cyclo-photocoagulation with phacoemulsification and combined Hydrus microstent with phacoemulsification Safety and efficacy of micropulse transscleral cyclophotocoagulation in eyes affected by advanced primary glaucoma Micropulse transscleral cyclophotocoagulation in the treatment of secondary ocular hypertension in the eyes with vitreous hemorrhage Continuous-wave Transscleral Cyclophotocoagulation (CW-TSCPC) Continuous-wave Transscleral Cyclophotocoagulation (CW-TSCPC) Performed with the Cyclo G6® using G-Probe® and G-Probe Illuminate® delivery devices, offering a cost- effective, safe, and effective non-incisional glaucoma care solution. Dedicated symposium on Continuous-wave and MicroPulse laser Associacion Argentina de Glaucoma Symposium - Continuous Diode and Micropulse Laser: The practice, its scope and current result MicroPulse® Laser Trabeculoplasty (MLT) Supported by Iridex 532 nm, 577 nm, and 810 nm laser platforms, MLT is a reasonable first-line therapy to address concerns of patient compliance with medical therapy, reduce patient costs and avoid medication side effects. Stela Vujosevic, MD, PhD, FEBO; Head of Medical Retina Unit at the University Eye Clinic, MultiMedica in Milan, Italy, commented, “Since 2009, I have been researching, and clinically applying, Iridex’ MicroPulse technology for safe and efficacious treatment of retinal disorders. More recently, my colleagues and I investigated the changes in intraocular pressure, functional parameters, and multimodal imaging in patients with ocular hypertension after MicroPulse Laser Trabeculoplasty. We are excited to share our research at EGS.” For more information, please contact your Iridex sales professional or Iridex customer service at 1.650.940.4700 or customerservice@Iridex.com. About Iridex In 2024, Iridex Corporation celebrates its 35th anniversary as a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven therapy for targeted sight- threatening eye conditions. Iridex’ products treat glaucoma, diabetic macular edema, and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.Iridex.com. Iridex Media Contact Joan Stauffer Director, Marketing & Clinical Communications jstauffer@Iridex.com isigma Tue, 11 Jun 2024 11:24:00 GMT f1397696-738c-4295-afcd-943feb885714:63 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=20#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=20 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=20&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=20 Laser Platform Supports Family of Consumable Probes and Appliances Including Recently Patented MicroPulse® P3 Disposable Mountain View, Calif., February 23, 2015 — Iridex Corporation (Nasdaq:IRIX) today announced that it will debut Cyclo G6, the Company’s first laser platform dedicated to the treatment of glaucoma, at this year’s annual congress of the American Glaucoma Society (AGS).  The AGS annual congress is being held February 26 – March 1, 2015, at San Diego’s Hotel del Coronado. Potentially 1,000 members from more than 17 countries are expected to attend the event.  The Cyclo G6 system, which was recently cleared by the US Food and Drug Administration (FDA), is designed to treat patients diagnosed with a range of glaucoma disease states and features the Company’s proprietary MicroPulse tissue-sparing technology and a family of single use probes that connect to an intuitive, user-friendly laser console.  MicroPulse offers a repeatable, minimally invasive approach to slowing the progress of the disease and pushing off the need for more invasive surgical intervention. In addition to the product unveiling, Iridex announced that a scientific poster presentation entitled, “MicroPulse Trans-scleral Cyclophotocoagulation (mTSCPC) for the Treatment of Glaucoma using the MicroPulse P3 Device,” will feature results from early clinical application of the new MicroPulse P3 disposable.  The poster will be presented on Friday, February 27, from 7-8 am PT and is authored by leading glaucoma specialists Drs. Nathan Radcliffe, Ike Ahmed, Jeffrey Kammer, Anup Khatana, Robert Noecker and Steven Vold. "Glaucoma is a chronic disease with an increasing incidence rate that is in need of innovative interventions to preserve vision," said inventor of the MicroPulse P3 device, Professor Paul Chew, MBBS, MMed(Ophth), FRCSEd, FRCOphth, FAMS of the National University of Singapore.  “A MicroPulse based consumable appliance with a characteristic high safety profile that leaves future treatment options open, is clinically repeatable, and that does not require incisional surgery, is a very compelling alternative." “Our proprietary Cyclo G6 platform allows Iridex to participate in both hardware and the faster growing procedural side of the glaucoma market, representing a new and more predictable recurring revenue stream,” stated Will Moore, Iridex President and CEO.  “The cost and logistics of administering glaucoma medications is a burden to both the patient and healthcare organizations; furthermore, patients using prescribed medications have a poor record of compliance.  Thus, a durable, cost-effective solution continues to be our focus as the world continues the trend toward value-based medicine.” Glaucoma is the leading cause of adult irreversible blindness.  It is estimated that more than 4 million people in the US and approximately 60 million worldwide are afflicted with glaucoma today. About Iridex Iridex Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. Iridex is dedicated to a standard of excellence, offering superior technology for superior results. Iridex products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the Iridex website at http://www.Iridex.com/.   Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the markets in which the Company operates, trends in treatment and product usage, product plans and future product releases, regulatory approvals, usage and efficacy of Company products, future financial results and the Company’s strategic plans and objectives. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 28, 2013, which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.   Iridex Contact:                                           Investor Contact:   Jim Mackaness                                               Matt Clawson CFO & COO                                                  Pure Communications, Inc. 650-940-4700                                                 949-370-8500                                                                         matt@purecommunicationsinc.com   host Sat, 28 Feb 2015 03:06:00 GMT f1397696-738c-4295-afcd-943feb885714:20